Switch to:
Also traded in: Germany, Mexico, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.03
NAS:SHPG's Cash to Debt is ranked lower than
98% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. NAS:SHPG: 0.03 )
Ranked among companies with meaningful Cash to Debt only.
NAS:SHPG' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 1.32 Max: No Debt
Current: 0.03
Equity to Asset 0.43
NAS:SHPG's Equity to Asset is ranked lower than
75% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:SHPG: 0.43 )
Ranked among companies with meaningful Equity to Asset only.
NAS:SHPG' s Equity to Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.58 Max: 0.85
Current: 0.43
0.25
0.85
Interest Coverage 1.80
NAS:SHPG's Interest Coverage is ranked lower than
97% of the 458 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:SHPG: 1.80 )
Ranked among companies with meaningful Interest Coverage only.
NAS:SHPG' s Interest Coverage Range Over the Past 10 Years
Min: 1.57  Med: 27.36 Max: 55.13
Current: 1.8
1.57
55.13
F-Score: 5
Z-Score: 1.12
M-Score: -1.62
WACC vs ROIC
10.92%
3.27%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 5.67
NAS:SHPG's Operating margin (%) is ranked higher than
75% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -78.20 vs. NAS:SHPG: 5.67 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:SHPG' s Operating margin (%) Range Over the Past 10 Years
Min: -56.61  Med: 22.5 Max: 35.13
Current: 5.67
-56.61
35.13
Net-margin (%) 1.09
NAS:SHPG's Net-margin (%) is ranked higher than
71% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. NAS:SHPG: 1.09 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:SHPG' s Net-margin (%) Range Over the Past 10 Years
Min: -59.59  Med: 16.4 Max: 56.55
Current: 1.09
-59.59
56.55
ROE (%) 0.57
NAS:SHPG's ROE (%) is ranked higher than
75% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. NAS:SHPG: 0.57 )
Ranked among companies with meaningful ROE (%) only.
NAS:SHPG' s ROE (%) Range Over the Past 10 Years
Min: -90.17  Med: 17.82 Max: 49.38
Current: 0.57
-90.17
49.38
ROA (%) 0.26
NAS:SHPG's ROA (%) is ranked higher than
77% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. NAS:SHPG: 0.26 )
Ranked among companies with meaningful ROA (%) only.
NAS:SHPG' s ROA (%) Range Over the Past 10 Years
Min: -37.5  Med: 9.76 Max: 31.55
Current: 0.26
-37.5
31.55
ROC (Joel Greenblatt) (%) 10.32
NAS:SHPG's ROC (Joel Greenblatt) (%) is ranked higher than
81% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. NAS:SHPG: 10.32 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:SHPG' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -396.76  Med: 110.47 Max: 345.44
Current: 10.32
-396.76
345.44
Revenue Growth (3Y)(%) 15.20
NAS:SHPG's Revenue Growth (3Y)(%) is ranked higher than
67% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. NAS:SHPG: 15.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:SHPG' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -0.8  Med: 11.8 Max: 26.7
Current: 15.2
-0.8
26.7
EBITDA Growth (3Y)(%) 18.10
NAS:SHPG's EBITDA Growth (3Y)(%) is ranked higher than
71% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. NAS:SHPG: 18.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:SHPG' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -1.9  Med: 20.75 Max: 34.2
Current: 18.1
-1.9
34.2
EPS Growth (3Y)(%) 21.50
NAS:SHPG's EPS Growth (3Y)(%) is ranked higher than
77% of the 511 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. NAS:SHPG: 21.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:SHPG' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -7.3  Med: 30.6 Max: 68.7
Current: 21.5
-7.3
68.7
» NAS:SHPG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

SHPG Guru Trades in Q4 2015

Andreas Halvorsen 137,198 sh (New)
Paul Singer 53,943 sh (New)
Steven Cohen 115,800 sh (+115700.00%)
Pioneer Investments 15,699 sh (+30.62%)
Jim Simons 278,112 sh (+23.22%)
Ken Fisher 33,954 sh (+9.30%)
John Paulson 6,844,800 sh (+0.58%)
Murray Stahl 6,000 sh (unchged)
First Eagle Investment 4,830 sh (unchged)
Samuel Isaly 82,128 sh (unchged)
Leon Cooperman Sold Out
» More
Q1 2016

SHPG Guru Trades in Q1 2016

David Dreman 154 sh (New)
Lee Ainslie 1,630 sh (New)
First Eagle Investment 47,032 sh (+873.75%)
Steven Cohen 197,200 sh (+70.29%)
Ken Fisher 39,657 sh (+16.80%)
Jim Simons 313,212 sh (+12.62%)
John Paulson 7,071,050 sh (+3.31%)
Murray Stahl 6,000 sh (unchged)
Pioneer Investments 15,699 sh (unchged)
Paul Tudor Jones 80,000 sh (unchged)
John Paulson 58,000 sh (unchged)
Samuel Isaly 82,128 sh (unchged)
Paul Singer Sold Out
Andreas Halvorsen 130,870 sh (-4.61%)
» More
Q2 2016

SHPG Guru Trades in Q2 2016

Tweedy Browne Global Value 6,803 sh (New)
Jeff Auxier 1,712 sh (New)
Mario Gabelli 5,874 sh (New)
Tweedy Browne 42,247 sh (New)
Third Avenue Management 47,840 sh (New)
Keeley Asset Management Corp 17,723 sh (New)
Jeremy Grantham 28,297 sh (New)
Daniel Loeb 950,000 sh (New)
Mairs and Power 182,790 sh (New)
Leon Cooperman 204,100 sh (New)
John Buckingham 19,575 sh (New)
Julian Robertson 120,554 sh (New)
Paul Singer 39,372 sh (New)
Steve Mandel 2,529,148 sh (New)
Andreas Halvorsen 1,162,787 sh (+788.51%)
Pioneer Investments 35,875 sh (+128.52%)
Murray Stahl 8,068 sh (+34.47%)
First Eagle Investment 56,549 sh (+20.24%)
Lee Ainslie 1,920 sh (+17.79%)
Ken Fisher 44,092 sh (+11.18%)
John Paulson 88,000 sh (unchged)
Samuel Isaly 82,128 sh (unchged)
Jim Simons Sold Out
David Dreman 140 sh (-9.09%)
John Paulson 5,194,600 sh (-26.54%)
Steven Cohen 130,100 sh (-34.03%)
» More
Q3 2016

SHPG Guru Trades in Q3 2016

Lee Ainslie 570,907 sh (+29634.74%)
Ken Fisher 166,168 sh (+276.87%)
Leon Cooperman 356,484 sh (+74.66%)
Steven Cohen 224,900 sh (+72.87%)
Third Avenue Management 68,224 sh (+42.61%)
Tweedy Browne Global Value 6,803 sh (unchged)
Kyle Bass 110,000 sh (unchged)
John Paulson 60,000 sh (unchged)
Jeff Auxier 1,712 sh (unchged)
Samuel Isaly 82,128 sh (unchged)
Jeremy Grantham Sold Out
Paul Singer Sold Out
John Buckingham 19,504 sh (-0.36%)
Keeley Asset Management Corp 17,322 sh (-2.26%)
David Dreman 134 sh (-4.29%)
Daniel Loeb 900,000 sh (-5.26%)
First Eagle Investment 53,037 sh (-6.21%)
Murray Stahl 7,267 sh (-9.93%)
John Paulson 4,667,800 sh (-10.14%)
Tweedy Browne 36,304 sh (-14.07%)
Steve Mandel 1,694,675 sh (-32.99%)
Andreas Halvorsen 764,762 sh (-34.23%)
Mairs and Power 119,577 sh (-34.58%)
Julian Robertson 78,154 sh (-35.17%)
Pioneer Investments 15,699 sh (-56.24%)
Mario Gabelli 1,242 sh (-78.86%)
» More
» Details

Insider Trades

Latest Guru Trades with SHPG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:REGN, NAS:BIIB, OTCPK:CSLLY, NAS:ALXN, OTCPK:NONOF, NAS:VRTX, NAS:INCY, OTCPK:ALIOY, NAS:BMRN, OTCPK:GIKLY, NAS:MDVN, OTCPK:UCBJY, NAS:CELG, OTCPK:GMXAY, OTCPK:NVZMF, NAS:SGEN, NAS:ALKS, NAS:TSRO, NAS:JAZZ, NAS:GILD » details
Traded in other countries:S7E.Germany, SHPG N.Mexico, SHP.UK, SHPGF.USA,
Shire PLC is a specialty biopharmaceutical company that focuses on developing and marketing specialty medicines that address unmet patient needs.

Shire PLC is a biotech company incorporated and registered in Jersey on January 28, 2008. The Company is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of medicines to meet unmet patient needs. Its Products include FIRAZYR, LDX, NATPAR, SHP609, GATTEX, INTUNIV, TYVENSE, VENVANSE, OBIZUR, HEMOFIL, FOZNOL among others. The Company develops products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a franchise in Oncology.

Ratios

vs
industry
vs
history
P/E(ttm) 136.65
SHPG's P/E(ttm) is ranked lower than
90% of the 250 Companies
in the Global Biotechnology industry.

( Industry Median: 27.27 vs. SHPG: 136.65 )
Ranked among companies with meaningful P/E(ttm) only.
SHPG' s P/E(ttm) Range Over the Past 10 Years
Min: 12.4  Med: 26.06 Max: 162.3
Current: 136.65
12.4
162.3
Forward P/E 10.36
SHPG's Forward P/E is ranked higher than
78% of the 55 Companies
in the Global Biotechnology industry.

( Industry Median: 17.39 vs. SHPG: 10.36 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 75.45
SHPG's PE(NRI) is ranked lower than
81% of the 248 Companies
in the Global Biotechnology industry.

( Industry Median: 27.60 vs. SHPG: 75.45 )
Ranked among companies with meaningful PE(NRI) only.
SHPG' s PE(NRI) Range Over the Past 10 Years
Min: 12.87  Med: 23.02 Max: 106.93
Current: 75.45
12.87
106.93
Price/Owner Earnings (ttm) 40.74
SHPG's Price/Owner Earnings (ttm) is ranked lower than
61% of the 142 Companies
in the Global Biotechnology industry.

( Industry Median: 28.19 vs. SHPG: 40.74 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
SHPG' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 11.33  Med: 24.04 Max: 72.9
Current: 40.74
11.33
72.9
P/B 1.78
SHPG's P/B is ranked higher than
74% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. SHPG: 1.78 )
Ranked among companies with meaningful P/B only.
SHPG' s P/B Range Over the Past 10 Years
Min: 1.7  Med: 5.48 Max: 14.15
Current: 1.78
1.7
14.15
P/S 4.66
SHPG's P/S is ranked higher than
70% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 10.41 vs. SHPG: 4.66 )
Ranked among companies with meaningful P/S only.
SHPG' s P/S Range Over the Past 10 Years
Min: 2.25  Med: 4.68 Max: 9.23
Current: 4.66
2.25
9.23
POCF 18.48
SHPG's POCF is ranked higher than
51% of the 186 Companies
in the Global Biotechnology industry.

( Industry Median: 19.60 vs. SHPG: 18.48 )
Ranked among companies with meaningful POCF only.
SHPG' s POCF Range Over the Past 10 Years
Min: 7.66  Med: 17.14 Max: 26.94
Current: 18.48
7.66
26.94
EV-to-EBIT 153.82
SHPG's EV-to-EBIT is ranked lower than
95% of the 252 Companies
in the Global Biotechnology industry.

( Industry Median: 19.98 vs. SHPG: 153.82 )
Ranked among companies with meaningful EV-to-EBIT only.
SHPG' s EV-to-EBIT Range Over the Past 10 Years
Min: -16.1  Med: 16.7 Max: 173.7
Current: 153.82
-16.1
173.7
EV-to-EBITDA 29.45
SHPG's EV-to-EBITDA is ranked lower than
68% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 16.24 vs. SHPG: 29.45 )
Ranked among companies with meaningful EV-to-EBITDA only.
SHPG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -19.6  Med: 13.45 Max: 33.2
Current: 29.45
-19.6
33.2
PEG 3.86
SHPG's PEG is ranked lower than
66% of the 95 Companies
in the Global Biotechnology industry.

( Industry Median: 2.10 vs. SHPG: 3.86 )
Ranked among companies with meaningful PEG only.
SHPG' s PEG Range Over the Past 10 Years
Min: 0.47  Med: 1.08 Max: 4.43
Current: 3.86
0.47
4.43
Shiller P/E 54.46
SHPG's Shiller P/E is ranked lower than
53% of the 58 Companies
in the Global Biotechnology industry.

( Industry Median: 48.79 vs. SHPG: 54.46 )
Ranked among companies with meaningful Shiller P/E only.
SHPG' s Shiller P/E Range Over the Past 10 Years
Min: 43.42  Med: 106.17 Max: 469
Current: 54.46
43.42
469
Current Ratio 1.25
SHPG's Current Ratio is ranked lower than
85% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. SHPG: 1.25 )
Ranked among companies with meaningful Current Ratio only.
SHPG' s Current Ratio Range Over the Past 10 Years
Min: 0.52  Med: 1.72 Max: 7.43
Current: 1.25
0.52
7.43
Quick Ratio 0.57
SHPG's Quick Ratio is ranked lower than
91% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. SHPG: 0.57 )
Ranked among companies with meaningful Quick Ratio only.
SHPG' s Quick Ratio Range Over the Past 10 Years
Min: 0.4  Med: 1.51 Max: 7.07
Current: 0.57
0.4
7.07
Days Inventory 299.72
SHPG's Days Inventory is ranked lower than
83% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 128.70 vs. SHPG: 299.72 )
Ranked among companies with meaningful Days Inventory only.
SHPG' s Days Inventory Range Over the Past 10 Years
Min: 126.5  Med: 190.58 Max: 299.72
Current: 299.72
126.5
299.72
Days Sales Outstanding 109.45
SHPG's Days Sales Outstanding is ranked lower than
75% of the 601 Companies
in the Global Biotechnology industry.

( Industry Median: 61.72 vs. SHPG: 109.45 )
Ranked among companies with meaningful Days Sales Outstanding only.
SHPG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.71  Med: 67.39 Max: 109.45
Current: 109.45
47.71
109.45

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.48
SHPG's Dividend Yield is ranked lower than
87% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 1.46 vs. SHPG: 0.48 )
Ranked among companies with meaningful Dividend Yield only.
SHPG' s Dividend Yield Range Over the Past 10 Years
Min: 0.23  Med: 0.41 Max: 0.7
Current: 0.48
0.23
0.7
Dividend Payout 0.41
SHPG's Dividend Payout is ranked lower than
59% of the 127 Companies
in the Global Biotechnology industry.

( Industry Median: 0.31 vs. SHPG: 0.41 )
Ranked among companies with meaningful Dividend Payout only.
SHPG' s Dividend Payout Range Over the Past 10 Years
Min: 0.04  Med: 0.26 Max: 1.27
Current: 0.41
0.04
1.27
Dividend Growth (3y) 16.70
SHPG's Dividend Growth (3y) is ranked higher than
72% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 8.50 vs. SHPG: 16.70 )
Ranked among companies with meaningful Dividend Growth (3y) only.
SHPG' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 15.5 Max: 57.9
Current: 16.7
0
57.9
Forward Dividend Yield 0.48
SHPG's Forward Dividend Yield is ranked lower than
87% of the 231 Companies
in the Global Biotechnology industry.

( Industry Median: 1.39 vs. SHPG: 0.48 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 1.04
SHPG's Yield on cost (5-Year) is ranked lower than
67% of the 293 Companies
in the Global Biotechnology industry.

( Industry Median: 1.66 vs. SHPG: 1.04 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
SHPG' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.5  Med: 0.89 Max: 1.52
Current: 1.04
0.5
1.52
3-Year Average Share Buyback Ratio -2.20
SHPG's 3-Year Average Share Buyback Ratio is ranked higher than
83% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. SHPG: -2.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SHPG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -50.3  Med: -2.1 Max: 0.4
Current: -2.2
-50.3
0.4

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.06
SHPG's Price/Projected FCF is ranked higher than
81% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 2.84 vs. SHPG: 1.06 )
Ranked among companies with meaningful Price/Projected FCF only.
SHPG' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.91  Med: 1.56 Max: 2.67
Current: 1.06
0.91
2.67
Price/Median PS Value 1.00
SHPG's Price/Median PS Value is ranked lower than
58% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. SHPG: 1.00 )
Ranked among companies with meaningful Price/Median PS Value only.
SHPG' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.52  Med: 0.95 Max: 2.68
Current: 1
0.52
2.68
Price/Peter Lynch Fair Value 3.72
SHPG's Price/Peter Lynch Fair Value is ranked lower than
75% of the 64 Companies
in the Global Biotechnology industry.

( Industry Median: 1.71 vs. SHPG: 3.72 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
SHPG' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.54  Med: 1.27 Max: 4.25
Current: 3.72
0.54
4.25
Earnings Yield (Greenblatt) (%) 0.61
SHPG's Earnings Yield (Greenblatt) (%) is ranked higher than
75% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. SHPG: 0.61 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SHPG' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.6  Med: 5.5 Max: 8.4
Current: 0.61
0.6
8.4
Forward Rate of Return (Yacktman) (%) 21.10
SHPG's Forward Rate of Return (Yacktman) (%) is ranked higher than
60% of the 119 Companies
in the Global Biotechnology industry.

( Industry Median: 15.80 vs. SHPG: 21.10 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
SHPG' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 1.5  Med: 2.4 Max: 28.9
Current: 21.1
1.5
28.9

More Statistics

Revenue (TTM) (Mil) $9,306
EPS (TTM) $ 1.55
Beta1.62
Short Percentage of Float0.38%
52-Week Range $147.60 - 210.33
Shares Outstanding (Mil)301.06

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 10,031 13,680 17,732 19,570
EPS ($) 13.37 16.03 19.58 24.44
EPS w/o NRI ($) 13.37 16.03 19.58 24.44
EPS Growth Rate
(3Y to 5Y Estimate)
12.71%
Dividends Per Share ($) 0.91 1.24 1.82
» More Articles for NAS:SHPG

Headlines

Articles On GuruFocus.com
Julian Robertson Sells Delta Air Lines, Alphabet Dec 07 2016 
John Paulson's Largest 3rd Quarter Trades Dec 01 2016 
Momenta Pharmaceuticals Announces Positive Results for Humira Biosimilar Nov 30 2016 
Samuel Isaly Makes 9 New Buys in 3rd Quarter Nov 04 2016 
Martin Whitman's Top Recent Investments Oct 12 2016 
John Paulson’s Health Care Picks Plunge in Flat Year for Sector Oct 06 2016 
Whitman's Third Avenue Buys 3 Pharma Stocks in 3rd Quarter Sep 27 2016 
Mairs and Power Buys Walt Disney, Exits Baxalta Sep 27 2016 
Third Avenue Value Fund 3rd Quarter Letter Sep 14 2016 
Hedge Funds Love Liberty and John Malone Aug 26 2016 

More From Other Websites
Allergan Unhappy with Patent Office Decision to Allow Mylan Challenge to Restasis Patents Dec 09 2016
Best Midcap Stocks To Buy According To Billionaire Loeb Dec 09 2016
3 Footsie value stocks for growth and income? Dec 06 2016
Blog Coverage Shire Announced Successful Results of its Phase III Investigational Study of... Dec 05 2016
Better buy: GlaxoSmithKline plc vs Shire plc Dec 05 2016
5 Healthcare Stocks Billionaires Love The Most Dec 04 2016
Shire Reports on Four Decades of Real-World Safety Experience With FEIBA® Dec 02 2016
Shire Loses Ground To Allergan In Thanksgiving Week Dry-Eye Scripts Dec 02 2016
SHIRE PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and... Dec 02 2016
Topline Results of Phase 3 Investigational Study of VONVENDI™ Meets Primary Endpoint Effectively... Dec 02 2016
Coverage initiated on Shire plc by Societe Generale Dec 02 2016
John Paulson's Largest 3rd Quarter Trades Dec 01 2016
SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits Dec 01 2016
Is Smart Money Turning More Positive on Bed Bath & Beyond Inc. (BBBY)? Dec 01 2016
Total Voting Rights Dec 01 2016
What Does Smart Money Think about Avery Dennison Corp (AVY)? Dec 01 2016
Momenta/Shire's Humira Biosimilar Meets Study Objective Nov 30 2016
Momenta stock jumps nearly 10% on positive late-stage results for Humira biosimilar Nov 29 2016
Amicus Tumbles on Lengthy Delay to U.S. Fabry Drug FDA Filing Plan Nov 28 2016
5 Healthcare Stocks Hedge Funds Are Dumping Like Crazy Nov 28 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)